Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug

 
• By Alaric DeArment
  
Handshake of businessmen
Sentynl signed a development and asset purchase agreement for Cyprium's CUTX-101 for Menkes disease, which has approved therapy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip